← FDA DRUG APPROVALS

FDA NDA · NDA209203

DUZALLO

Sponsor: IRONWOOD PHARMS INC

APPLICATION
NDA209203
TYPE
NDA
ORIGINAL APPROVAL
2017-08-18
LATEST ACTION
2017-08-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

DUZALLO · ReferenceDiscontinued
ALLOPURINOL 200MG, LESINURAD 200MG · TABLET · ORAL
DUZALLO · ReferenceDiscontinued
ALLOPURINOL 300MG, LESINURAD 200MG · TABLET · ORAL

Approval history

2017-08-18Type 4 - New Combination · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →